Volume | 35,987 |
|
|||||
News | - | ||||||
Day High | 6.77 | Low High |
|||||
Day Low | 5.84 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Telomir Pharmaceuticals Inc | TELO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
6.27 | 5.84 | 6.77 | 6.05 | 5.94 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
652 | 35,987 | $ 6.07 | $ 218,502 | - | 4.76 - 20.72 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 1 | $ 6.045 | USD |
Telomir Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
179.14M | 29.61M | - | 0 | -13.07M | -0.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Telomir Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TELO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 6.31 | 7.19 | 5.80 | 6.47 | 58,131 | -0.26 | -4.12% |
1 Month | 6.63 | 7.40 | 5.56 | 6.37 | 32,106 | -0.58 | -8.75% |
3 Months | 8.75 | 9.39 | 4.76 | 6.98 | 42,116 | -2.70 | -30.86% |
6 Months | 7.00 | 20.72 | 4.76 | 8.00 | 57,435 | -0.95 | -13.57% |
1 Year | 7.00 | 20.72 | 4.76 | 8.00 | 57,435 | -0.95 | -13.57% |
3 Years | 7.00 | 20.72 | 4.76 | 8.00 | 57,435 | -0.95 | -13.57% |
5 Years | 7.00 | 20.72 | 4.76 | 8.00 | 57,435 | -0.95 | -13.57% |
Telomir Pharmaceuticals Description
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. |